James Morden
Overview
Explore the profile of James Morden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al.
Lancet Oncol
. 2020 Nov;
21(11):1443-1454.
PMID: 33152284
Background: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour...
2.
Schuster E, Gellert P, Segal C, Lopez-Knowles E, Buus R, Chon U Cheang M, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914010
Purpose: Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy number alterations (SCNAs),...
3.
Gao Q, Lopez-Knowles E, Chon U Cheang M, Morden J, Ribas R, Sidhu K, et al.
Breast Cancer Res
. 2020 Jan;
22(1):2.
PMID: 31892336
Background: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy...
4.
Gao Q, Lopez-Knowles E, Chon U Cheang M, Morden J, Ribas R, Sidhu K, et al.
JNCI Cancer Spectr
. 2019 Jul;
2(2):pky005.
PMID: 31360844
To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and...
5.
Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al.
J Clin Oncol
. 2018 Dec;
37(3):178-189.
PMID: 30523750
Purpose: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects...
6.
Gellert P, Segal C, Gao Q, Lopez-Knowles E, Martin L, Dodson A, et al.
Nat Commun
. 2016 Nov;
7:13294.
PMID: 27827358
Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in...
7.
Lopez-Knowles E, Gao Q, Chon U Cheang M, Morden J, Parker J, Martin L, et al.
Breast Cancer Res
. 2016 Apr;
18(1):39.
PMID: 27036195
Background: Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements...
8.
Bliss J, Kilburn L, Coleman R, Forbes J, Coates A, Jones S, et al.
J Clin Oncol
. 2011 Nov;
30(7):709-17.
PMID: 22042946
Purpose: Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3...
9.
Bate J, Yung C, Hoschler K, Sheasby L, Morden J, Taj M, et al.
Clin Infect Dis
. 2010 Nov;
51(12):e95-104.
PMID: 21067352
Background: Children with cancer have an increased susceptibility to influenza infection. The objective of this study was to assess the immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer....